Pharmaceutical Executive April 4, 2024
Otsuka and Click Therapeutics co-developed Rejoyn, a digital therapeutic for MDD.
FDA approved Rejoyn, making it the first digital therapeutic to receive approval for the treatment of major depressive disorder (MDD). The therapeutic is approved to be used alongside clinician-managed outpatient care for patients 22-years or older.
Otsuka Pharmaceutical and Click Therapeutics co-developed the digital therapeutic, which uses both cognitive emotional training exercises and brief therapeutic lessons. According to a press release from Otsuka,1 the digital therapeutic is available only through a prescription.
In the press release, Otsuka executive vice president and chief medical officer John Krause, M.D., Ph.D., said, “Rejoyn represents a novel and exciting adjunctive treatment option to address major depressive disorder (MDD) symptoms that complements the current...
Today's Sponsors
Today's Sponsor